Page 20 - Confidence Interval News Today

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 -- HUTCHMED Limited ; class=js-l-obf link link--blue

An analysis of data from more than 60,000 women details associations between specific chronotypes and risk of unhealthy lifestyle behaviors as well as risk of developing type 2 diabetes.

1. In this phase three open-label randomized trial, concizumab prophylaxis reduced the annualized bleeding rate in patients with hemophilia with inhibitors as compared to placebo control. 2. While overall and serious adverse events were not significantly different between control and concizumab groups, the trial was temporarily suspended due to nonfatal thromboembolic events in three patients

1. In this randomized controlled trial, among patients living with human immunodeficiency virus (HIV) at low-to-moderate risk of cardiovascular disease, pitavastatin calcium was superior to placebo in reducing the risk of a major adverse cardiovascular event (MACE). 2. The trial was stopped early due to evidence of the efficacy and safety of pitavastatin. Evidence Rating

Data from longest reported follow-up for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer demonstrate consistent, durable benefits of Opdivo plus Yervoy vs. chemotherapy at...

An analysis of data from more than 20,000 women in the New York City A1c registry details the prevalence of and drivers behind racial/ethnic disparities in the incidence of type 2 diabetes following gestational diabetes mellitus.

This report describes flu vaccine effectiveness data from five South American countries during the 2023 Southern Hemisphere flu season.

1. In this pooled analysis of randomized controlled trials, low-dose glucocorticoids taken over a two-year period did not increase patient blood pressure. 2. Low-dose glucocorticoid use was associated with an increase in weight of one kilogram on average. Evidence Rating Level: 1 (Excellent) Study Rundown: Glucocorticoids are commonly used in the management of rheumatoid arthritis

1. In this randomized controlled trial, among patients living with human immunodeficiency virus (HIV) at low-to-moderate risk of cardiovascular disease, pitavastatin calcium was superior to placebo in reducing the risk of a major adverse cardiovascular event (MACE). 2. The trial was stopped early due to evidence of the efficacy and safety of pitavastatin. Evidence Rating

1. In this randomized controlled trial, an oral orexin receptor 2 (OX2R) agonist (TAK-994) was associated with improvements in wakefulness, sleepiness, and cataplexy incidence among patients with narcolepsy type 1. 2. TAK-994 was also associated with liver enzyme elevation and drug-induced hepatotoxicity. Evidence Rating Level: 1 (Excellent) Study Rundown: Narcolepsy is a rare chronic disorder